INVENTIVA: Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
INVENTIVA: Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases Revenues of €0.1m in Q1 2021 Decision by AbbVie to move into Phase IIb clinical development with cedirogant in psoriasis, following promising results in its Phase Ib clinical trial Daix (France), May 12, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other dis...